Treatment of hepatic amyloid light‐chain amyloidosis with bortezomib and dexamethasone in a liver transplant patient

E-ISSN： 1872-034x|45|10|E150-E155

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.45, Iss.10, 2015-10, pp. : E150-E155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Patient with Multiple Myeloma, Amyloidosis and Light-Chain Deposition Disease in Kidneys with a Long Survival

Acta Haematologica, Vol. 101, Iss. 4, 1999-07 ,pp. : 202-205

Karger

Access to resources Recommend Favorite

Characteristics and Long-Term Outcome of Patients with Systemic Immunoglobulin Light-Chain Amyloidosis

Acta Haematologica, Vol. 133, Iss. 4, 2014-12 ,pp. : 336-346

Karger

Access to resources Recommend Favorite

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 804-813

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : E60-E65

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy

Acta Haematologica, Vol. 135, Iss. 3, 2016-01 ,pp. : 172-190

Karger

Access to resources Recommend Favorite